Celgene Corporation

Celgene — Shareholder Meeting (May 2016)

19 slides from Celgene's shareholder meeting presentation, May 10, 2016

  1. Slide 1: Additional 2016 Proxy Materials Celgene

    Additional 2016 Proxy Materials Celgene (NASDAQ: CELG)

  2. Slide 2: Forward Looking Statements and Adjusted Financial Information

    Forward Looking Statements and Adjusted Financial Information 2 This presentation contains forward - looking statements, which are generally statements that are not historical facts . Forward - looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estima

  3. Slide 3: Agenda

    Agenda • Company Overview • Celgene Proposal to Amend the 2008 Equity Plan • Celgene Proposal to Ratify the By - Law Amendment on Forum Selection • Stockholder Proposal on Special Meetings • Stockholder Proposal on Proxy Access 3

  4. Slide 4: We Are A Leading Global Biopharmaceutical Company

    We Are A Leading Global Biopharmaceutical Company 4 Unique R&D Capability • Expertise in hematology, oncology, and immunology • Diverse technology platforms • Rich pipeline – 70 programs in preclinical development – 32 treatments in clinical trials – 24 pivotal / phase III programs underway • Operat

  5. Slide 5: We Have a Strong 5-Year Financial Track Record

    $1.89 $2.45 $2.98 $3.71 $4.71 2011 2012 2013 2014 2015 We Have a Strong 5 - Year Financial Track Record 5 $1.24 $1.31 $1.51 $1.65 $2.04 2011 2012 2013 2014 2015 Notes: 1) Net Product Sales adjusted for 2011, 2) CAGR calculated using 2010 to 2015, 3) Adjusted EPS is split - adjusted for 2011 - 2013.

  6. Slide 6: Our Performance Has Led to Significant Value Creation

    Our Performance Has Led to Significant Value Creation CELG NBI BTK COMP SPX 1 - year 7.1% 11.4% 10.9% 5.7% - 0.7% 3 - year 205.2% 147.4% 146.5% 65.8% 43.3% 5 - year 305.0% 264.9% 193.9% 88.8% 62.5% 10 - year 639.3% 348.0% 460.1% 127.1% 63.7% 6 Note: Periods are for calendar year; amounts based on qu

  7. Slide 7: Operational Achievements Are Expected to Sustain Our Growth Profile Through 2020

    Operational Achievements Are Expected to Sustain Our Growth Profile Through 2020 7 2015 2017E 2020E Net Product Sales ($B) 18% CAGR >$21 $9.2 $12.7 - $13 2015 2017E 2020E 23% CAGR >$13 $4.71 $6.75 - $7.00 Adjusted EPS ($) Key Operational Achievements x Executing Global Launches for Blockbuster Brand

  8. Slide 8: Our Equity Plan Is a Critical Tool to Delivering on Our 2020 Financial Targets

    Our Equity Plan Is a Critical Tool to Delivering on Our 2020 Financial Targets The primary purpose of the Plan is to enable us to attract, retain, and motivate key employees who are important to our success by aligning their interests with those of our stockholders: • Our Plan has broad participatio

  9. Slide 9: The Plan Has Several Stockholder-Friendly Features

    The Plan Has Several Stockholder - Friendly Features The Plan has several features designed to protect stockholder interests and promote effective corporate governance, including: • The Plan is administered by the Compensation Committee comprised solely of independent directors • Stock options have

  10. Slide 10: We Are Requesting 17.5 Million Additional Shares for the Equity Plan

    We Are Requesting 17.5 Million Additional Shares for the Equity Plan 10 Key Consideration for Stockholders: • We believe that without such approval we would lose a critical stockholder alignment feature of our compensation framework and would not be able to compete effectively in a biopharma market

  11. Slide 11: Existing Stock Options Outstanding and Shares Available

    11 Total % of Shares Outstanding Stock Options Outstanding, all plans (1) 75,990,781 9.8% Full - Value Awards Outstanding, all plans 7,894,683 1.0% Shares Available for Awards, all plans (2) (3) 35,834,888 4.6% 1) As of April 18, 2016, the range of the exercise prices of stock options outstanding un

  12. Slide 12: Our Strong Performance Has Created a Significant Overhang with In-the-Money Options

    Our Strong Performance Has Created a Significant Overhang with In - the - Money Options Year Granted (Calendar Year) Employee Options Outstanding Employee Options Exercisable Weighted Avg. Exercise Price Weighted Avg. Contractual Term (in years) Options Held by Current NEOs 2015 11,117,068 1,292,572

  13. Slide 13: Proposal Five: Ratify Amendment to By-Laws on Forum Selection

    Proposal Five: Ratify Amendment to the Company’s By - Laws on Forum Selection for Internal Corporate Claims 13 The Board recommends that stockholders VOTE FOR this proposal to ratify the Amendment to the Company’s by - laws adding a new Section 6.5 which provides that Internal Corporate Claims may o

  14. Slide 14: Proposal Six: Stockholder Proposal on Right to Call a Special Meeting

    Proposal Six: Stockholder Proposal Seeking By - Law Amendment Granting Stockholder’s the Right to Call a Special Meeting 14 An individual stockholder, John Chevedden , submitted Proposal Six requesting the Board to take the steps necessary to amend the by - laws and each appropriate governing docume

  15. Slide 15: Proposal Seven: Stockholder Proposal for Proxy Access

    Proposal Seven: Stockholder Proposal for Proxy Access 15 UAW Retiree Medical Benefits Trust submitted Proposal Seven requesting the Board to adopt and present for stockholder approval a 3%, 3 - Year proxy access by - law. After careful consideration, the Board has concluded that this stockholder pro

  16. Slide 16: Conclusion

    Conclusion We recommend stockholders vote: x FOR Proposal Three to amend our Stock Incentive Plan x FOR Proposal Five to ratify the by - law amendment on Forum Selection x AGAINST Proposal Six on Special Meetings x AGAINST Proposal Seven on Proxy Access 16

  17. Slide 17: Additional 2016 Proxy Materials Celgene

    Additional 2016 Proxy Materials Celgene (NASDAQ: CELG)

  18. Slide 18: Reconciliation Tables

    Reconciliation Tables 18 2015 2014 2013 2012 2011 2010 Net income attributable to Celgene - GAAP 1,602.0$ 1,999.9$ 1,449.9$ 1,456.2$ 1,318.1$ 880.5$ Before tax adjustments: Net product sales: Sales of products exited it to be exited: Pharmion (1) - - - - (5.4) (8.2) Abraxis (1) - - - - (21.3) (15.9)

  19. Slide 19: Reconciliation Tables: Explanation of adjustments

    Reconciliation Tables 19 Explanation of adjustments: (1) Exclude sales related to non-core former Pharmion Corp., or Pharmion, and Abraxis BioScience Inc., or Abraxis products to be divested. (2) Exclude the estimated impact of activities arising from the acquisition of Abraxis that are not related

Celgene — Shareholder Meeting (May 2016) on 6ix